ASM Microbe 2026
June 4-7, 2026 – Washington, DC, USA
 ADLM 2026
July 26-30, 2026 – Anaheim, CA, USA
    1. Home
    2. New Products
    3. Complement Component 5a Antibodies for Assay Development

    Complement Component 5a Antibodies for Assay Development

      Introduction

      Complement component 5 (C5) is a protein from the complement system playing an important role in inflammatory and cell killing process. C5a as a cell signaling protein can initiate an adaptive immune response and release cytokines with its ligand, C5a receptor (C5aR). The over-activation of C5a anaphylatoxin with C5aR can cause cytokine storm, endothelial inflammation and thrombosis in severe forms of COVID-19. Creative Diagnostics now provides a broad range of well-validated antibodies, antigens as well as research grade biosimilars with abundant quality control data in comprehensive applications.

      Background

      The complement cascade as a multifunction system is crucial to innate host immunity. Over the past few years, C5a inhibition has garnered attention as a new therapeutic strategy for many inflammatory diseases. For instance, Eculizumab binds to C5 and prevents its cleavage into C5a and C5b, which blocks the formation of membrane attack complex (MAC). It has been used as a treatment for paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS).

      Complement Component 5a Antibodies for Assay DevelopmentFig.1 The impact of Covid-19 on the complement system activation pathways

      Researchers also found high concentrations of C5a in COVID-19 patients with severe multisystem organ failure, pulmonary lesions, endotheliitis lesions and microthrombi symptom. Therefore, the C5a/C5aR axis blockade could make contributions to attenuating the cytokine storm and COVID-19-related organ syndromes. Thus, Vilobelimab and Eculizumab are believed to be potential therapy strategies for COVID-19 patients in severe condition. Additionally, it has been suggested that C5a with other known biomarkers can act together as a prognostic model of COVID-19 severity with an increased predictive capacity.

      Reagents Solutions

      Creative Diagnostics has developed C5 antibodies for use in common research applications: sELISA, Blocking, Neutralization, WB and other functional assays. All of them are produced from a standardized production process and well validated to ensure the highest quality, which can be used in a variety of model species. We also offer C5a antigens from human species with high purity. These reagents will be valuable assets to support your research.

      References

      1. Horiuchi T, Tsukamoto H. Complement-targeted therapy: development of C5- and C5a-targeted inhibition. Inflammation and Regeneration. 2016;36(1):11.
      2. Maglakelidze N, Manto KM, Craig TJ. A Review: Does Complement or the Contact System Have a Role in Protection or Pathogenesis of COVID-19? Pulmonary Therapy. 2020;6(2):169-76.
      3. Mahmudpour M, Roozbeh J, Keshavarz M, Farrokhi S, Nabipour I. COVID-19 cytokine storm: The anger of inflammation. Cytokine. 2020;133:155151.
      4. Carvelli J, Demaria O, Vély F, Batista L, Chouaki Benmansour N, Fares J, et al. Association of COVID-19 inflammation with activation of the C5a–C5aR1 axis. Nature. 2020;588(7836):146-50.
      5. Li J, Liu B. The roles and potential therapeutic implications of C5a in the pathogenesis of COVID-19-associated coagulopathy. Cytokine Growth Factor Rev. 2021;58:75-81.
      6. Chouaki Benmansour N, Carvelli J, Vivier E. Complement cascade in severe forms of COVID-19: Recent advances in therapy. European Journal of Immunology. 2021:1-8.
      7. Cyprian FS, Suleman M, Abdelhafez I, Doudin A, Masud Danjuma IM, Mir FA, et al. Complement C5a and Clinical Markers as Predictors of COVID-19 Disease Severity and Mortality in a Multi-Ethnic Population. Frontiers in Immunology. 2021;12.
      Antibodies
      Target Cat_NProduct NameSourceApplication
      Human C5a DCABY-4009Anti-C5a monoclonal antibody, clone 306004 Mouse ELISA(Cap), Neut, WB
      [Low endotoxin]      		Inquiry    
      DCABY-4277Anti-C5a monoclonal antibody, clone 306000 [Biotin] Mouse ELISA(Det)Inquiry    
      Mouse C5a CABT-L277Anti-C5a monoclonal antibody, clone 306219 Rat ELISA(Cap), Block, Neut, WB
      [Low endotoxin]      		Inquiry    
      CABT-L278Anti-C5a polyclonal antibody, Biotin Goat ELISA(Det), Block, Neut, WBInquiry    
      Human C5 CABT-Z701HAnti-C5 monoclonal antibody, Eculizumab (Biosimilar) Chimeric FuncS
      [Low endotoxin]      		Inquiry    
      CABT-CS534Anti-C5 monoclonal antibody, Vilobelimab (Biosimilar) Chimeric IA
      [Biosimilar]      		Inquiry    
      Mouse C5CABT-47920MHAnti-C5 monoclonal antibody, clone 046-10.2.2 (10-04) Mouse ELISA, WB, FuncSInquiry    
      Human C5aRCABT-L3174Anti-Human C5aR1 monoclonal antibody, clone 458325 Mouse FC, NeutInquiry    
      Product Highlights
      • Highly purified antibodies with high-efficiency and increased potency.
      • Recombinant chimeric antibodies with excellent batch consistency.
      • Suitable for a range of applications: sELISA, FC, WB, Blocking, Neutralization, and other Functional Assays.
      • Research grade biosimilars and in vivo grade antibodies are also available.
      Antigens
      Target Cat_NProduct NameNature
      Human C5aDAG4668Human C5a Anaphylatoxin NativeInquiry    
      DAG4669Human C5a desArg Anaphylatoxin NativeInquiry    
      Product Highlights
      • Purified from human serum
      • Purity: >97% by SDS-PAGE
      • Endotoxin: Typically < 0.1 EU/µg
      Inquiry Basket